The Pharmacy Times® Oncology resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.
What can we help you find?
Avapritinib was awarded FDA approval on Jan 9.
The ErbB inhibitors, gefitinib, erbstatin, and tryphostin AG825, inhibit a cell signaling process controlling the death-rate of neutrophils, immune cells, which cause damage to the lungs.
Dawn Hershman, MD, MS, offers some potential treatments for aromatase inhibitor-caused arthralgia in breast cancer patients. This video was filmed at the 2019 San Antonio Breast Cancer Symposium.
A discussion of the PAOLO-1 trial regimen and the rationale behind combining olaparib and bevacizumab as post-chemotherapy maintenance.
Belantamab mafodotin has the potential for durable responses in patients with multiple myeloma whose disease has relapsed or is resistant to standard therapies.
Because of the vulnerabilities of CDK4/6i-resistant tumors, researchers believe that it is imperative to improve the survival of this group of patients.
The rise in value-based reimbursement models has required oncology care providers to assume an unprecedented level of accountability.
The decline in the cancer mortality rate attributed to immunotherapy methods, early detection, and treatment.
Maurie Markman, MD, leads a discussion on the design and results of the PRIMA trial, and how it has impacted practice.
After injecting the flu vaccine into a tumor cell, researchers found that the injection either slowed the growth or shrunk the tumor itself.
Key opinion leaders discuss the importance of HRD testing, with special consideration of tissue testing versus somatic testing.
This medication is the first precision therapy approved to treat a genomically defined population of patients with GIST, according to Blueprint Medicines.